JLJang Hee Lee

Jang Hee Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jang Hee Lee has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Ahrong Ham

    Department of Hematology and Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul 07985, Republic of Korea

    1 shared publication
  • Byung-In Moon

    Cancer Center for Women, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea

    1 shared publication
  • Doyil Kim

    Department of Surgery, Hallym University Sacred Heart Hospital, Hallym University, Republic of Korea

    1 shared publication
  • Esther Kim

    Department of Hematology and Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul 07985, Republic of Korea

    1 shared publication
  • Hee-Joon Kang

    Department of Surgery, Dongtan Sacred Heart Hospital, Hallym University, Republic of Korea

    1 shared publication
  • Hye Ah Lee

    Clinical Trial Center, Ewha Womans University Mokdong Hospital, Seoul, Korea

    1 shared publication

Latest Publications

  • Open Access

    Pathological characteristics and prognosis of very young patients with early breast cancer: a comparative analysis with older patients

    by Youri Park, Jin Hoon Nam, Yeonjoo Kwon, Jung Ho Park, Sanghwa Kim, Young Ah Lim, Hee-Joon Kang, Doyil Kim, Janghee Lee

    Background and purpose: It has generally been established that younger breast cancer patients exhibit unfavorable biology and poorer prognosis. However, previous studies have not consistently demonstrated differences between younger and older patients. The objective of this study, therefore, was to compare pathological characteristics and prognosis in young patients (age ≤ 40 years) with early breast cancer with those of older patients (age ≥ 55 years).Patients/material and methods: Individuals diagnosed with early breast cancer (age ≤ 40 years) and those ≥ 55 years of age, who were treated at two hospitals between June 2003 and December 2019, were identified. Oncological outcomes, including recurrence-free survival (RFS), distant RFS (DRFS), and locoregional RFS (LRRFS), were compared between two groups. Kaplan–Meier survival curves and the Cox proportional hazards model were used to evaluate.Results: Data from 288 young (≤ 40 years) and 830 older (≥ 55 years) patients were included. Pathologically, younger patients exhibited a higher prevalence of high-grade tumors. There was no significant difference in RFS and DRFS between the younger and older patient groups (RFS: hazard ratio 1.11 [95% confidence intervals (CI) 0.74–1.66]; P = 0.613; DRFS: hazard ratio 1.03 [95% CI 0.65–1.62]; P = 0.897). However, LRRFS was unfavorable in younger patients (hazard ratio, 2.15; 95% CI, 1.03–4.49; P = 0.043). Subgroup analysis revealed a significant difference in LRRFS among hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients (hazard ratio 4.04 [95% CI 1.17–13.97]; P = 0.027); however, no significant difference was observed in other subtypes.Interpretation: Younger patients with breast cancer exhibited a higher frequency of high-grade tumors, although no differences were observed in RFS and DRFS. However, locoregional recurrence was more common among younger patients, especially HR-positive/HER2-negative breast cancer.

  • Open Access

    Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer

    by Esther Kim, Youra Lim, Ahrong Ham, Hyun Goo Kim, Jun Woo Lee, Jang Hee Lee, Joohyun Woo, Woosung Lim, Byung In Moon, Sei Hyun Ahn, et al.

    Introduction: In the treatment of hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer (MBC), the current guidelines recommend endocrine therapy combined with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as the preferred first-line treatment to preserve quality of life. Ribociclib is a CDK4/6 inhibitor that has been used in combination with aromatase inhibitors or fulvestrant in patients with HR+, HER2− metastatic breast cancer. Various adverse drug reactions associated with ribociclib have been reported, including cutaneous reactions, hepatotoxicity, and hematologic toxicity. In this study, we aimed to evaluate the clinical manifestations and risk factors of dermatologic toxicities in patients with metastatic breast cancer treated with ribociclib. Methods: This retrospective study included patients with metastatic/recurrent breast cancer who were prescribed ribociclib from April 2021 to December 2024 at a single institution. We retrospectively reviewed the medical records of these patients to identify the frequency of cutaneous adverse events, the time of onset, and the clinical characteristics of skin reactions. Logistic regression analysis was performed on several clinical factors, including body surface area (BSA) and concomitant medications, to identify risk factors associated with the occurrence of cutaneous adverse events. Results: A total of 110 patients with MBC were enrolled during the study period. The median age was 53 years (range, 28–82); all 110 patients (100.0%) were female; the median BSA was 1.56 m2 (range, 1.29–2.07); and 32 patients (29.1%) were premenopausal. Ribociclib plus letrozole was administered in 48 patients (43.6%) and ribociclib plus fulvestrant in 29 patients (26.4%). An additional 33 patients (30.0%) received ribociclib plus letrozole with a gonadotropin-releasing hormone (GnRH) agonist. Cutaneous adverse events occurred in 29 patients (26.4%), and the median time to onset was 84 days (range, 3–498). The cutaneous adverse event patterns included pruritus, erythematous macular rash, eczematous rash/contact dermatitis, vitiligo, urticarial reactions, polymorphous light eruption, toxic epidermal necrolysis (TEN), and desquamation. Grade 1 or 2 cutaneous adverse events occurred in 93.1% of patients; Grade 3 toxicity occurred in one patient; and Grade 4 toxicity, namely toxic epidermal necrolysis (TEN), was reported in one patient. Dose reduction was required in three patients (10.3%), and permanent discontinuation of ribociclib occurred in one patient. Clinical improvement was achieved in the majority of patients (86.2%) with cutaneous adverse events following supportive care. Logistic regression analysis revealed that age, Eastern Cooperative Oncology Group (ECOG) performance status, body surface area (BSA), treatment regimen, and use of cholesterol-lowering medications were not independently associated with the development of cutaneous adverse events. Conclusion: CDK4/6 inhibitors represent one of the most important treatment options for HR+/HER2− metastatic breast cancer. Regardless of their clinical efficacy, cutaneous adverse events remain a common source of patient discomfort. Therefore, careful clinical attention and appropriate supportive care are essential to improve patients' quality of life.